Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Partin

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Urology Case Reports|January 22, 2016
From the EditorsAlan Partin, Alan Wein
The New England Journal of Medicine|July 13, 2004
Progress toward identifying aggressive prostate cancerMario Eisenberger, Alan Partin
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerationsEli Rosenbaum, Alan Partin, Mario A Eisenberger
The Journal of Urology|August 25, 2011
Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomyAli Amin, Alan Partin, Jonathan I Epstein
Scientific Reports|September 1, 2022
Urinary marker panels for aggressive prostate cancer detectionTung-Shing Mamie Lih, Mingming Dong, Leslie Mangold, et al.
Journal of Proteome Research|June 9, 2021
Development of Parallel Reaction Monitoring Assays for the Detection of Aggressive Prostate Cancer Using Urinary GlycoproteinsMingming Dong, Tung-Shing Mamie Lih, Naseruddin Höti, et al.
Journal of Translational Autoimmunity|January 14, 2020
Angiotensin receptor autoantibodies as exposures that modify disease progression: Cross sectional, longitudinal and <i>in vitro</i> studies of prostate cancerAlka Jain, Haikoo Shah, Eleanor M Simonsick, et al.
Urology|September 17, 2013
Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostateSheila F Faraj, Roula Albadine, Alcides Chaux, et al.
Urologic Oncology|July 15, 2022
Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter studyEric A Klein, Alan Partin, Yair Lotan, et al.
Prostate Cancer and Prostatic Diseases|October 1, 2021
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studiesErik Margolis, Gordon Brown, Alan Partin, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Urology Case Reports|January 22, 2016
From the EditorsAlan Partin, Alan Wein
The New England Journal of Medicine|July 13, 2004
Progress toward identifying aggressive prostate cancerMario Eisenberger, Alan Partin
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerationsEli Rosenbaum, Alan Partin, Mario A Eisenberger
The Journal of Urology|August 25, 2011
Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomyAli Amin, Alan Partin, Jonathan I Epstein
Scientific Reports|September 1, 2022
Urinary marker panels for aggressive prostate cancer detectionTung-Shing Mamie Lih, Mingming Dong, Leslie Mangold, et al.
Journal of Proteome Research|June 9, 2021
Development of Parallel Reaction Monitoring Assays for the Detection of Aggressive Prostate Cancer Using Urinary GlycoproteinsMingming Dong, Tung-Shing Mamie Lih, Naseruddin Höti, et al.
Journal of Translational Autoimmunity|January 14, 2020
Angiotensin receptor autoantibodies as exposures that modify disease progression: Cross sectional, longitudinal and <i>in vitro</i> studies of prostate cancerAlka Jain, Haikoo Shah, Eleanor M Simonsick, et al.
Urology|September 17, 2013
Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostateSheila F Faraj, Roula Albadine, Alcides Chaux, et al.
Urologic Oncology|July 15, 2022
Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter studyEric A Klein, Alan Partin, Yair Lotan, et al.
Prostate Cancer and Prostatic Diseases|October 1, 2021
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studiesErik Margolis, Gordon Brown, Alan Partin, et al.
Pageof 3